A pharmacovigilance analysis of ALK-TKI inhibitors conducted through the FDA Adverse Event Reporting System (FAERS) identified several important safety signals, including pulmonary arterial hypertension, rectal perforation, myasthenia gravis, and photosensitivity (63). The gene discussed is ALK; the disease is pulmonary arterial hypertension.